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Recommended Pediatric Immunization Schedules — United States - 2018
Figure 1. Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2018. 
(FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). 
These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. 
To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded in gray.
NOTE: The above recommendations must be read along with the footnotes of this schedule. 
Vaccine Birth 1 mo 2 mos 4 mos 6 mos 9 mos 12 mos 15 mos 18 mos
19-23 
mos
2-3 yrs 4-6 yrs 7-10 yrs 11-12 yrs 13-15 yrs 16 yrs 17-18 yrs
Hepatitis B1  (HepB)
Rotavirus2  (RV) RV1 (2-dose 
series); RV5 (3-dose series)
Diphtheria, tetanus, & acellular 
pertussis3  (DTaP: <7 yrs)






Influenza7  (IIV) 
Measles, mumps, rubella8  (MMR)
Varicella9  (VAR)
Hepatitis A1 0  (HepA) 
Meningococcal1 1  (MenACWY-D 
>9 mos; MenACWY-CRM ≥2 mos) 
Tetanus, diphtheria, & acellular 
pertussis1 3  (Tdap: >7 yrs)




2nd dose1st doseSee footnote 11
See footnote 
14






4th dose3rd dose2nd dose1st dose
2-dose series, See footnote 10
4th dose3rd dose2nd dose1st dose
2nd dose1st dose






5th dose4th dose3rd dose2nd dose1st dose
3rd dose2nd dose1st dose




No recommendationRange of recommended ages  
for certain high-risk  groups
Range of recommended 
ages for all children
Range of recommended ages 
for catch-up immunization
Range of recommended ages for non-high-risk 
groups that may receive vaccine, subject to 
individual clinical decision making
FIGURE 2. Catch-up immunization schedule for persons aged 4 months–18 years who start late or who are more than 1 month behind—United States, 2018.
The figure below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between 
doses. Use the section appropriate for the child’s age. Always use this table in conjunction with Figure 1 and the footnotes that follow.





Minimum Interval Between Doses
Dose 1 to Dose 2 Dose 2 to Dose 3 Dose 3 to Dose 4 Dose 4 to Dose 5




for first dose is 
14 weeks, 6 days
4 weeks 4 weeks
2
Maximum age for final dose is 8 months, 0 days.
Diphtheria, tetanus, and 
acellular pertussis3 6 weeks 4 weeks 4 weeks 6 months 6 months
3
Haemophilus influenzae 
type b4 6 weeks
4 weeks 
if first dose was administered 
before the 1st birthday.
8 weeks (as final dose) 
if first dose was administered at age 
12 through 14 months.
No further doses needed if first 
dose was administered at age 15 
months or older.
4 weeks4 
if current age is younger than 12 months and first dose was administered at younger than age 7 months, 
and at least 1 previous dose was PRP-T (ActHib, Pentacel, Hiberix) or unknown.
8 weeks and age 12 through 59 months (as final dose)4 
• if current age is younger than 12 months and first dose was administered at age 7 through 11 
months; 
OR
• if current age is 12 through 59 months and first dose was administered before the 1st birthday, and 
second dose administered at younger than 15 months;  
OR
• if both doses were PRP-OMP (PedvaxHIB; Comvax) and were administered before the 1st birthday.
No further doses needed if previous dose was administered at age 15 months or older.
8 weeks (as final dose) 
This dose only necessary for chil-
dren age 12 through 59 months 





if first dose administered before the 
1st birthday.
8 weeks (as final dose for healthy 
children)
if first dose was administered at the 
1st birthday or after.
No further doses needed 
for healthy children if first dose was 
administered at age 24 months or 
older.
4 weeks 
if current age is younger than 12 months and previous dose given at <7 months old.
8 weeks (as final dose for healthy children) 
if previous dose given between 7-11 months (wait until at least 12 months old); 
OR
if current age is 12 months or older and at least 1 dose was given before age 12 months.
No further doses needed for healthy children if previous dose administered at age 24 months or older.
8 weeks (as final dose) 
This dose only necessary for chil-
dren aged 12 through 59 months 
who received 3 doses before age 12 
months or for children at high risk 
who received 3 doses at any age.
Inactivated poliovirus6 6 weeks 4 weeks6
4 weeks6 if current age is < 4 years
6 months (as final dose) if current age is 4 years or older
6 months6 (minimum age 4 years for 
final dose).
Measles, mumps, rubella8 12 months 4 weeks
Varicella9 12 months 3 months




6 weeks 8 weeks11 See footnote 11 See footnote 11








tetanus, diphtheria, and 
acellular pertussis13
7 years13 4 weeks 
4 weeks 
if first dose of DTaP/DT was administered before the 1st birthday. 
6 months (as final dose) 
if first dose of DTaP/DT or Tdap/Td was administered at or after the 1st birthday.
6 months if first dose of DTaP/DT  
was administered before the 1st 
birthday.
Human papillomavirus14 9 years Routine dosing intervals are recommended.14
Hepatitis A10 N/A 6 months
Hepatitis B1 N/A 4 weeks 8 weeks and at least 16 weeks after first dose.
Inactivated poliovirus6 N/A 4 weeks
6 months6
A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months 
after the previous dose.
A fourth dose of IPV is indicated if all 
previous doses were administered 
at <4 years or if the third dose was 
administered <6 months after the 
second dose.
Measles, mumps, rubella8 N/A 4 weeks
Varicella9 N/A
3 months if younger than age 13 
years. 
4 weeks if age 13 years or older.
NOTE: The above recommendations must be read along with the footnotes of this schedule. 
CR-010648    3/18
For more information visit:
www.scdhec.gov/scimmunize
Footnotes — Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, UNITED STATES, 2018 
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.  
For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.
Additional information
• For information on contraindications and precautions for the use of a vaccine, consult the General Best Practice Guidelines for Immunization and relevant ACIP 
statements, at www.cdc.gov/vaccines/hcp/acip-recs/index.html. 
• For calculating intervals between doses, 4 weeks = 28 days. Intervals of >4 months are determined by calendar months.
• Within a number range (e.g., 12–18), a dash (–) should be read as “through.”
• Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum 
interval or minimum age should not be counted as valid and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by 
the recommended minimum interval. For further details, see Table 3-1, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice 
Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
• Information on travel vaccine requirements and recommendations is available at wwwnc.cdc.gov/travel/.
• For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice 
Guidelines for Immunization, at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html; and Immunization in Special Clinical Circumstances. (In: 
Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of 
Pediatrics, 2015:68-107).
• The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All routine child and 
adolescent vaccines are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information; see www.hrsa.gov/vaccinecompensation/
index.html.
1.  Hepatitis B (HepB) vaccine. (minimum age: birth) 
Birth Dose (Monovalent HepB vaccine only):
• Mother is HBsAg-Negative: 1 dose within 24 
hours of birth for medically stable infants >2,000 
grams. Infants <2,000 grams administer 1 dose at 
chronological age 1 month or hospital discharge.
• Mother is HBsAg-Positive: 
 ɱ Give HepB vaccine and 0.5 mL of HBIG (at 
separate anatomic sites) within 12 hours of 
birth, regardless of birth weight.
 ɱ Test for HBsAg and anti-HBs at age 9–12 
months. If HepB series is delayed, test 1–2 
months after final dose.
• Mother’s HBsAg status is unknown: 
 ɱ Give HepB vaccine within 12 hours of birth, 
regardless of birth weight. 
 ɱ For infants <2,000 grams, give 0.5 mL of HBIG 
in addition to HepB vaccine within 12 hours of 
birth. 
 ɱ Determine mother’s HBsAg status as soon as 
possible. If mother is HBsAg-positive, give 0.5 
mL of HBIG to infants >2,000 grams as soon as 
possible, but no later than 7 days of age.
Routine Series:
• A complete series is 3 doses at 0, 1–2, and 6–18 
months. (Monovalent HepB vaccine should be 
used for doses given before age 6 weeks.)
• Infants who did not receive a birth dose should 
begin the series as soon as feasible (see Figure 2).
• Administration of 4 doses is permitted when a 
combination vaccine containing HepB is used after 
the birth dose.
• Minimum age for the final (3rd or 4th) dose: 24 
weeks. 
• Minimum Intervals: Dose 1 to Dose 2: 4 weeks / 
Dose 2 to Dose 3: 8 weeks / Dose 1 to Dose 3: 16 
weeks. (When 4 doses are given, substitute “Dose 
4” for “Dose 3” in these calculations.)
Catch-up vaccination:
• Unvaccinated persons should complete a 3-dose 
series at 0, 1–2, and 6 months.
• Adolescents 11–15 years of age may use an 
alternative 2-dose schedule, with at least 4 months 
between doses (adult formulation Recombivax 
HB only).
• For other catch-up guidance, see Figure 2.
2.  Rotavirus vaccines. (minimum age: 6 weeks)
Routine vaccination:
 Rotarix: 2-dose series at 2 and 4 months.
 RotaTeq: 3-dose series at 2, 4, and 6 months.
If any dose in the series is either RotaTeq or 
unknown, default to 3-dose series.
Catch-up vaccination:
• Do not start the series on or after age 15 weeks, 0 
days.
• The maximum age for the final dose is 8 months, 0 
days.
• For other catch-up guidance, see Figure 2.
3.  Diphtheria, tetanus, and acellular pertussis (DTaP) 
vaccine. (minimum age: 6 weeks [4 years for 
Kinrix or Quadracel])
Routine vaccination:
• 5-dose series at 2, 4, 6, and 15–18 months, and 4–6 
years. 
 ɱ Prospectively: A 4th dose may be given as 
early as age 12 months if at least 6 months 
have elapsed since the 3rd dose.
 ɱ Retrospectively: A 4th dose that was 
inadvertently given as early as 12 months may 
be counted if at least 4 months have elapsed 
since the 3rd dose. 
Catch-up vaccination:
• The 5th dose is not necessary if the 4th dose was 
administered at 4 years or older.
• For other catch-up guidance, see Figure 2.
Footnotes — Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, UNITED STATES, 2018 
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.  
For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.
Additional information
• For information on contraindications and precautions for the use of a vaccine, consult the General Best Practice Guidelines for Immunization and relevant ACIP 
statements, at www.cdc.gov/vaccines/hcp/acip-recs/index.html. 
• For calculating intervals between doses, 4 weeks = 28 days. Intervals of >4 months are determined by calendar months.
• Within a nu ber range (e.g., 12–18), a dash (–) should be read as “through.”
• Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum 
interval or minimum age should not be counted as valid and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by 
the recommended minimu  interval. For further details, see Table 3-1, Rec mmended and minimum ages and int rvals between vaccine doses, in General Best Practice 
Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
• Information on travel vaccine requirements and recommendations is available at wwwnc.cdc.gov/travel/.
• For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice 
Guidelines for Immunization, at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html; and Immunization in Special Clinical Circumstances. (In: 
Kimberlin DW, Brady MT, Jackson MA, Lo g SS, eds. Red Book: 2015 report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of 
Pediatrics, 2015:68-107).
• The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All routine child and 
adolescent vaccines are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information; see www.hrsa.gov/vaccinecompensation/
index.html.
1.  Hepatitis B (HepB) vaccine. (minimum age: birth) 
Birth Dose (Monovalent HepB vaccine only):
• Mother is HBsAg-Negative: 1 dose within 24 
hours of birth for medically stable infants >2,000 
grams. Infants <2,000 grams administer 1 dose at 
chronological age 1 month or hospital discharge.
• Mot er is HBsAg-Positive: 
 ɱ Give HepB vaccine and 0.5 mL of HBIG (at 
separate anatomic sites) within 12 hours of 
birth, regardless of birth weight.
 ɱ Test for HBsAg and anti-HBs at age 9–12 
months. If HepB series is delayed, test 1–2 
months after final dose.
• Mother’s HBsAg status is unknown: 
 ɱ Give HepB v ccine within 12 hours of birth, 
regardless of birth weight. 
 ɱ For infants <2,000 grams, give 0.5 mL of HBIG 
in addition to HepB vaccine within 12 hours of 
birth. 
 ɱ Determine mother’s HBsAg status as soon as 
possible. If mother is HBsAg-positive, give 0.5 
mL of HBIG to infants >2,000 grams as soon as 
possible, but no later than 7 days of age.
Routine Series:
• A complete series is 3 doses at 0, 1–2, and 6–18 
months. (Monovalent HepB vaccine should be 
used for doses given before age 6 weeks.)
• Infants who did not receive a birth dose should 
begin the series as soon as feasible (see Figure 2).
• Administration of 4 doses is permitted when a 
combination vaccine containing HepB is used after 
the birth dose.
• Minimum age for the final (3rd or 4th) dose: 24 
weeks. 
• Minimum Intervals: Dose 1 to Dose 2: 4 weeks / 
Dose 2 to Dose 3: 8 weeks / Dose 1 to Dose 3: 16 
weeks. (When 4 doses are given, substitute “Dose 
4” for “Dose 3” in these calculations.)
Catch-up vaccination:
• Unvaccinated persons should complete a 3-dose 
series at 0, 1–2, and 6 months.
• Adolescents 11–15 years of age may use an 
alternative 2-dose schedule, with at least 4 months 
between doses (adult formulation Recombivax 
HB only).
• For other catch-up guidance, see Figure 2.
2.  Rotavirus vaccines. (minimum age: 6 weeks)
Routine vaccination:
 Rotarix: 2-dose series at 2 and 4 months.
 RotaTeq: 3-dose series at 2, 4, and 6 months.
If any dose in the series is either RotaTeq or 
unknown, default to 3-dose series.
Catch-up vaccination:
• Do not start the series on or after age 15 weeks, 0 
days.
• The maximum age for the final dose is 8 months, 0 
days.
• For other catch-up guidance, see Figure 2.
3.  Diphtheria, tetanus, and acellular pertussis (DTaP) 
vaccine. (minimum age: 6 weeks [4 years for 
Kinrix or Quadracel])
Routine vaccination:
• 5-dose series at 2, 4, 6, and 15–18 months, and 4–6 
years. 
 ɱ Prospectively: A 4th dose may be given as 
early as age 12 months if at least 6 months 
have elapsed since the 3rd dose.
 ɱ Retrospectively: A 4th dose that was 
inadvertently given as early as 12 months may 
be counted if at least 4 months have elapsed 
since the 3rd dose. 
Catch-up vaccination:
• The 5th dose is not necessary if the 4th dose was 
administered at 4 years or older.
• For other catch-up guidance, see Figure 2.
Footnotes — Recommended Immunization Schedule f r Children and Adolescents Aged 18 Years or Younger, UNITED STATES, 2018 
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.  
For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.
Additional information
• For information on contraindications and precautions for the use of a vaccine, consult the General Best Practice Guidelines for Immunization and relevant ACIP 
statements, at www.cdc.gov/vaccines/hcp/acip-recs/index.html. 
• For calculating intervals between doses, 4 weeks = 28 days. Intervals of >4 months are determined by calendar months.
• Within a number range (e.g., 12–18), a dash (–) should be read as “through.”
• Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum 
interval or minimum age should not be counted as valid and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by 
the recommended minimum interval. For further details, see Table 3-1, Recommended and minimum ages and intervals bet een vaccine doses, in General Best Practice 
Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
• Information on travel vaccine requirements and recommendations is available at wwwnc.cdc.gov/travel/.
• For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice 
Guidelines for Immunization, at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html; and Immunization in Special Clinical Circumstances. (In: 
Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of 
Pediatrics, 2015:68-107).
• The National Vaccine Injury Compensation Program (VICP) is a o-fault alternative to the traditional legal system for resolving vaccine injury claims. All routine child and 
adolescent vaccines are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information; see www.hrsa.gov/vaccinecompensation/
index.html.
1.  Hepatitis B (HepB) vaccine. (minimum age: birth) 
Birth Dose (Monovalent HepB vaccine only):
• Mother is HBsAg-Negative: 1 dose within 24 
hours of birth for medically stable infants >2,000 
grams. Infants <2,000 grams administer 1 dose at 
chronological age 1 month or hospital discharge.
• Mother is HBsAg-Positive: 
 ɱ Give HepB vaccine and 0.5 mL of HBIG (at 
separate anatomic sites) within 12 hours of 
birth, regardless of birth weight.
 ɱ Test for HBsAg and anti-HBs at age 9–12 
months. If HepB series is delayed, test 1–2 
months after final dose.
• Mother’s HBsAg status is unknown: 
 ɱ Give HepB vaccine within 12 hours of birth, 
regardless of birth weight. 
 ɱ For infants <2,000 grams, give 0.5 mL of HBIG 
in addition to HepB vaccine within 12 hours of 
birth. 
 ɱ Determine mother’s HBsAg status as soon as 
possible. If mother is HBsAg-positive, give 0.5 
mL of HBIG to infants >2,000 grams as soon as 
possible, but no later than 7 days of age.
Routine Series:
• A complete series is 3 doses at 0, 1–2, and 6–18 
months. (Monovalent HepB vaccine should be 
used for doses given before age 6 weeks.)
• Infants who did not receive a birth dose should 
begin the series as soon as feasible (see Figure 2).
• Administration of 4 oses is permitted when a 
combination vaccine containing HepB is used after 
the birth dose.
• Minimum age for the final (3rd or 4th) dose: 24 
weeks. 
• Minimum Intervals: Dose 1 to D se 2: 4 weeks / 
Dose 2 to Dose 3: 8 weeks / Dose 1 to Dose 3: 16 
weeks. (When 4 doses are given, substitute “Dose 
4” for “Dose 3” in these calculations.)
Catch-up vaccination:
• Unvaccinated persons should complete a 3-dose 
series at 0, 1–2, and 6 months.
• Adolescents 11–15 years of age may use an 
alternative 2-dose schedule, with at least 4 months 
between doses (adult formulation Recombivax 
HB only).
• For other catch-up guidance, see Figure 2.
2.  Rotavirus vaccines. (minimum age: 6 weeks)
Routine vaccination:
 Rotarix: 2-dose series at 2 and 4 months.
 RotaTeq: 3-dose series at 2, 4, and 6 months.
If any dose in the series is either RotaTeq or 
unknown, default to 3-dose series.
Catch-up vaccination:
• Do not start the series on or after age 15 weeks, 0 
days.
• The maximum age for the final dose is 8 months, 0 
days.
• For other catch-up guidance, see Figure 2.
3.  Diphtheria, tetanus, and acellular pertussis (DT P) 
vaccine. (minimum age: 6 weeks [4 years for 
Kinrix or Quadracel])
Routine vaccination:
• 5-dose series at 2, 4, 6, and 15–18 months, and 4–6 
years. 
 ɱ Prospectively: A 4th dose may be given as 
early as age 12 months if at least 6 months 
have elapsed since the 3rd dose.
 ɱ Retrospectively: A 4th dose that was 
inadvertently given as early as 12 months may 
be counted if at least 4 months have elapsed 
since the 3rd dose. 
Catch-up vaccination:
• The 5th dose is not necessary if the 4th dose was 
administered at 4 years or older.
• For other catch-up guidance, see Figure 2.
Footnotes — Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Young r, UNITED STATES, 2018 
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.  
For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.
Additional information
• For information on contraindications and precautions for the use of a vaccine, consult the General Best Practice Guidelines for Immunization and relevant ACIP 
statements, at www.cdc.gov/vaccines/hcp/acip-recs/index.html. 
• For calculating intervals between doses, 4 weeks = 28 days. Intervals of >4 months are determined by calendar months.
• Within a number range (e.g., 12–18), a dash (–) should be read as “through.”
• Vaccine doses administered ≤4 days before the minimum age or interval are o sidered valid. Do es of any vaccine administered ≥5 days earlier than the minimum 
interval or minimum age should not be counted as valid and should b  repeated as a e-appropriate. The repeat dose should be spaced after the invalid dose by 
the recommended minimum interval. For further details, see Table 3-1, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice 
Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
• Information on travel vaccine requirements and recommendations is available at wwwnc.cdc.gov/travel/.
• For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice 
Guidelines for Immunization, at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html; and Immunization in Special Clinical Circumstances. (In: 
Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of 
Pediatrics, 2015:68-107).
• The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All routine child and 
adolescent vaccines are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information; see www.hrsa.gov/vaccinecompensation/
index.html.
1.  Hepatitis B (HepB) vaccine. (minimum age: birth) 
Birth Dose (Monovalent HepB vaccine only):
• Mother is HBsAg-Negative: 1 dose within 24 
hours of birth for medically stable infants >2,000 
grams. Infants <2,000 grams administer 1 dose at 
chronological age 1 month or hospital discharge.
• Mother is HBsAg-Positive: 
 ɱ Give HepB vaccine and 0.5 mL of HBIG (at 
separate anatomic sites) within 12 hours of 
birth, regardless of birth weight.
 ɱ Test for HBsAg and anti-HBs at age 9–12 
months. If HepB series is delayed, test 1–2 
months after final dose.
• Mother’s HBsAg status is unknown: 
 ɱ Give HepB vaccine within 12 hours of birth, 
regardless of birth weight. 
 ɱ For infants <2,000 grams, give 0.5 mL of HBIG 
in addition to HepB vaccine within 12 hours of 
birth. 
 ɱ Determine mother’s HBsAg status as soon as 
possible. If mother is HBsAg-positive, give 0.5 
mL of HBIG to infants >2,000 grams as soon as 
possible, but no later than 7 days of age.
Routine Series:
• A complete series is 3 doses at 0, 1–2, and 6–18 
months. (Monovalent HepB vaccine should be 
used for doses given before age 6 weeks.)
• Infants who did not receive a birth dose should 
begin the series as soon as feasible (see Figure 2).
• Administration of 4 doses is permitted when a 
combination vaccine containing HepB is used after 
the birth dose.
• Minimum age for the final (3rd or 4th) dose: 24 
weeks. 
• Minimum Intervals: Dose 1 to Dose 2: 4 weeks / 
Dose 2 to Dose 3: 8 weeks / Dose 1 to Dose 3: 16 
weeks. (When 4 doses are given, substitute “Dose 
4” for “Dose 3” in these calculations.)
Catch-up vaccination:
• Unvaccinated persons should complete a 3-dose 
series at 0, 1–2, and 6 months.
• Adolescents 11–15 years of age may use an 
alternative 2-dose schedule, with at least 4 months 
between doses (adult formulation Recombivax 
HB only).
• For other catch-up guidance, see Figure 2.
2.  Rotavirus vaccines. (minimum age: 6 weeks)
Routine vaccination:
 Rotarix: 2-dose series at 2 and 4 months.
 RotaTeq: 3-dose series at 2, 4, and 6 months.
If any dose in the series is either RotaTeq or 
unknown, default to 3-dose series.
Catch-up vaccination:
• Do not start the series on or after age 15 weeks, 0 
days.
• The maximum age for the final dose is 8 months, 0 
days.
• For other catch-up guidance, see Figure 2.
3.  Diphtheria, tetanus, and acellular pertussis (DTaP) 
vaccine. (minimum age: 6 weeks [4 years for 
Kinrix or Quadracel])
Routine vaccination:
• 5-dose series at 2, 4, 6, and 15–18 months, and 4–6 
years. 
 ɱ Prospectively: A 4th dose may be given as 
early as age 12 months if at least 6 months 
have elapsed since the 3rd dose.
 ɱ Retrospectively: A 4th dose that was 
inadvertently given as early as 12 months may 
be counted if at least 4 months have elapsed 
since the 3rd dose. 
Catch-up vaccination:
• The 5th dose is not necessary if the 4th dose was 
administered at 4 years or older.
• For other catch-up guidance, see Figure 2.
4.  Haemophilus influenzae type b (Hib) vaccine. 
(minimum age: 6 weeks) 
Routine vaccination: 
• ActHIB, Hiberix, or Pentacel: 4-dose series at 2, 4, 
6, and 12–15 months.
• PedvaxHIB: 3-dose series at 2, 4, and 12–15 months.
Catch-up vaccination: 
• 1st dose at 7–11 months: Give 2nd dose at least 4 
weeks later and 3rd (final) dose at 12–15 months or 
8 weeks after 2nd dose (whichever is later).
• 1st dose at 12–14 months: Give 2nd (final) dose at 
least 8 weeks after 1st dose.
• 1st dose before 12 months and 2nd dose before 
15 months: Give 3rd (final) dose 8 weeks after 2nd 
dose.
• 2 doses of PedvaxHIB before 12 months: Give 3rd 
(final) dose at 12–59 months and at least 8 weeks 
after 2nd dose.
• Unvaccinated at 15–59 months: 1 dose.
• For other catch-up guidance, see Figure 2. 
Special Situations:
• Chemotherapy or radiation treatment 
12–59 months 
 ɱ Unvaccinated or only 1 dose before 12 months: 
Give 2 doses, 8 weeks apart
 ɱ 2 or more doses before 12 months: Give 1 dose, 
at least 8 weeks after previous dose.
Doses given within 14 days of starting therapy or 
during therapy should be repeated at least 3 months 
after therapy completion.
• Hematopoietic stem cell transplant (HSCT)
• 3-dose series with doses 4 weeks apart starting 6 to 
12 months after successful transplant (regardless of 
Hib vaccination history).
• Anatomic or functional asplenia (including sickle 
cell disease)
12–59 months
 ɱ Unvaccinated or only 1 dose before 12 months: 
Give 2 doses, 8 weeks apart.
 ɱ 2 or more doses before 12 months: Give 1 dose, 
at least 8 weeks after previous dose.
Unimmunized* persons 5 years or older
 ɱ Give 1 dose
• Elective splenectomy
Unimmunized* persons 15 months or older




 ɱ Unvaccinated or only 1 dose before 12 
months: Give 2 doses 8 weeks apart.
 ɱ 2 or more doses before 12 months: Give 1 
dose, at least 8 weeks after previous dose.
Unimmunized* persons 5–18 years
 ɱ Give 1 dose
• Immunoglobulin deficiency, early component 
complement deficiency
12–59 months
 ɱ Unvaccinated or only 1 dose before 12 
months: Give 2 doses, 8 weeks apart.
 ɱ 2 or more doses before 12 months: Give 1 
dose, at least 8 weeks after previous dose.
*Unimmunized = Less than routine series (through 14 
months) OR no doses (14 months or older)
5.  Pneumococcal vaccines. (minimum age: 6 weeks 
[PCV13], 2 years [PPSV23])
Routine vaccination with PCV13:
• 4-dose series at 2, 4, 6, and 12–15 months.
Catch-up vaccination with PCV13:
• 1 dose for healthy children aged 24–59 months 
with any incomplete* PCV13 schedule
• For other catch-up guidance, see Figure 2.
Special situations: High-risk conditions: 
Administer PCV13 doses before PPSV23 if 
possible.
Chronic heart disease (particularly cyanotic 
congenital heart disease and cardiac failure); 
chronic lung disease (including asthma treated 
with high-dose, oral, corticosteroids); diabetes 
mellitus:
Age 2–5 years:
• Any incomplete* schedules with:
 ɱ 3 PCV13 doses: 1 dose of PCV13 (at least 8 
weeks after any prior PCV13 dose).
 ɱ <3 PCV13 doses: 2 doses of PCV13, 8 weeks 
after the most recent dose and given 8 weeks 
apart.
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose). 
Age 6-18 years:
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose).
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
Cerebrospinal fluid leak; cochlear implant:
Age 2–5 years:
• Any incomplete* schedules with:
 ɱ 3 PCV13 doses: 1 dose of PCV13 (at least 8 
weeks after any prior PCV13 dose).
 ɱ <3 PCV13 doses: 2 doses of PCV13, 8 weeks 
after the most recent dose and given 8 weeks 
apart.
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose). 
Age 6–18 years:
• No history of either PCV13 or PPSV23: 1 dose of 
PCV13, 1 dose of PPSV23 at least 8 weeks later.
• Any PCV13 but no PPSV23: 1 dose of PPSV23 at 
least 8 weeks after the most recent dose of PCV13
• PPSV23 but no PCV13: 1 dose of PCV13 at least 8 
weeks after the most recent dose of PPSV23.
Sickle cell disease and other hemoglobinopathies; 
anatomic or functional asplenia; congenital 
or acquired immunodeficiency; HIV infection; 
chronic renal failure; nephrotic syndrome; 
malignant neoplasms, leukemias, lymphomas, 
Hodgkin disease, and other diseases associated 
with treatment with immunosuppressive drugs 
or radiation therapy; solid organ transplantation; 
multiple myeloma:
Age 2–5 years:
• Any incomplete* schedules with:
 ɱ 3 PCV13 doses: 1 dose of PCV13 (at least 8 
weeks after any prior PCV13 dose).
 ɱ <3 PCV13 doses: 2 doses of PCV13, 8 weeks 
after the most recent dose and given 8 weeks 
apart.
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose) and a 2nd dose 
of PPSV23 5 years later.
Age 6–18 years:
• No history of either PCV13 or PPSV23: 1 dose of 
PCV13, 2 doses of PPSV23 (1st dose of PPSV23 
administered 8 weeks after PCV13 and 2nd dose of 
PPSV23 administered at least 5 years after the 1st 
dose of PPSV23).
• Any PCV13 but no PPSV23: 2 doses of PPSV23 (1st 
dose of PPSV23 to be given 8 weeks after  the most 
recent dose of PCV13 and 2nd dose of PPSV23 
administered at least 5 years after the 1st dose of 
PPSV23).
4.  Haemophilus influenzae type b (Hib) vaccine. 
(minimum age: 6 weeks) 
Routine vaccination: 
• ActHIB, Hiberix, or Pentacel: 4-dose series at 2, 4, 
6, and 12–15 months.
• PedvaxHIB: 3-dose series at 2, 4, and 12–15 months.
Catch-up vaccination: 
• 1st dose at 7–11 months: Give 2nd dose at least 4 
weeks later and 3rd (final) dose at 12–15 months or 
8 weeks after 2nd dose (whichever is later).
• 1st dose at 12–14 months: Give 2nd (final) dose at 
least 8 weeks after 1st dose.
• 1st dose before 12 months and 2nd dose before 
15 months: Give 3rd (final) dose 8 weeks after 2nd 
dose.
• 2 doses of PedvaxHIB before 12 months: Give 3rd 
(final) dose at 12–59 months and at least 8 weeks 
after 2nd dose.
• Unvaccinated at 15–59 months: 1 do e.
• For other catch-up guidance, see Figure 2. 
Special Situations:
• Chemotherapy or radiation treatment 
12–59 months 
 ɱ Unvaccinated or only 1 dose before 12 months: 
Give 2 doses, 8 weeks apart
 ɱ 2 or more doses before 12 months: Give 1 dose, 
at least 8 weeks after previous dose.
Doses given within 14 days of starting therapy or 
during therapy should be repeated at least 3 months 
after therapy completion.
• Hematopoietic stem cell transplant (HSCT)
• 3-dose series with doses 4 weeks apart starting 6 to 
12 months after successful transplant (regardless of 
Hib vaccination history).
• Anatomic or functional asplenia (including sickle 
cell disease)
12–59 months
 ɱ Unvaccinated or only 1 dose before 12 months: 
Give 2 doses, 8 weeks apart.
 ɱ 2 or more doses b fore 12 months: Give 1 dose, 
at least 8 w eks after previous dos .
Uni munized* persons 5 year or older
 ɱ Give 1 dose
• Elective splenectomy
Un m nized* pe sons 15 months or older




 ɱ Unvaccinated or only 1 dose before 12 
months: Give 2 doses 8 weeks apart.
 ɱ 2 or more doses before 12 months: Give 1 
dose, at least 8 weeks after previous dose.
Unimmunized* persons 5–18 years
 ɱ Give 1 dose
• Immunoglobulin deficiency, early co pone t 
complement deficiency
12–59 months
 ɱ Unvaccinated or only 1 dose before 12 
months: Give 2 doses, 8 weeks apart.
 ɱ 2 or more doses before 12 months: Give 1 
dose, at least 8 weeks after previous dose.
*Unimmunized = Less han routine series (through 14 
months) OR no doses (14 months or older)
5.  Pneumococcal vaccines. (minimum age: 6 weeks 
[PCV13], 2 years [PPSV23])
Routine vaccination with PCV13:
• 4-dose series at 2, 4, 6, and 12–15 months.
Catch-up vacci ation with PCV13:
• 1 dose for healthy children aged 24–59 onths 
with any incomplete* PCV13 schedule
• For other catch-up guidance, see Figure 2.
Special situations: High-risk conditions: 
Administer PCV13 doses before PPSV23 if 
possible.
Chronic heart disease (particularly cyanotic 
congenital heart disease and cardiac failure); 
chronic lung disease (including asthma treated 
with high-dose, oral, corticosteroids); diabetes 
mellitus:
Age 2–5 years:
• Any incomplete* schedules with:
 ɱ 3 PCV13 doses: 1 dose of PCV13 (at least 8 
weeks after any prior PCV13 dose).
 ɱ <3 PCV13 doses: 2 doses of PCV13, 8 weeks 
after the most recent d se and iven 8 w eks 
apart.
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose). 
Age 6-18 years:
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose).
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
Cerebrospinal fluid leak; cochlear implant:
Age 2–5 years:
• Any incomplete* schedules with:
 ɱ 3 PCV13 doses: 1 dose of PCV13 (at least 8 
weeks after any prior PCV13 dose).
 ɱ <3 PCV13 doses: 2 doses of PCV13, 8 weeks 
after the most recent dose and given 8 weeks 
apart.
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose). 
Age 6–18 years:
• No history of either PCV13 or PPSV23: 1 dose of 
PCV13, 1 dose of PPSV23 at least 8 weeks later.
• Any PCV13 but no PPSV23: 1 dose of PPSV23 at 
least 8 weeks after the most recent dose of PCV13
• PPSV23 but no PCV13: 1 dose of PCV13 at least 8 
weeks after the most recent dose of PPSV23.
Sickle cell disease and other hemoglobinopathies; 
anatomic or functional asplenia; congenital 
or acquired immunodeficiency; HIV infection; 
chronic renal failure; nephrotic syndrome; 
malignant neoplasms, leukemias, lymphomas, 
Hodgki  disease, and other diseas s associated 
with treatment with immunosuppressive drugs 
or radiation therapy; solid organ transplantation; 
multiple myeloma:
Age 2–5 years:
• Any incomplete* schedules with:
 ɱ 3 PCV13 doses: 1 dose of PCV13 (at least 8 
weeks after any prior PCV13 dose).
 ɱ <3 PCV13 doses: 2 doses of PCV13, 8 weeks 
after the most recent dose and given 8 weeks 
apart.
• No history of PPSV23: 1 dose of PPSV23 ( t least 8 
weeks after any prior PCV13 dose) and a 2nd dose 
of PPSV23 5 years later.
Age 6–18 years:
• No history of either PCV13 or PPSV23: 1 dose of 
PCV13, 2 doses of PPSV23 (1st dose of PPSV23 
administered 8 weeks after PCV13 and 2nd dose of 
PPSV23 administered at least 5 years after the 1st 
dose of PPSV23).
• Any PCV13 but no PPSV23: 2 doses of PPSV23 (1st 
dose of PPSV23 to be given 8 weeks after  the most 
recent dose of PCV13 and 2nd dose of PPSV23 
administered at least 5 years after the 1st dose of 
PPSV23).
4.  Haemophilus influenzae type b (Hib) vaccine. 
(minimum age: 6 weeks) 
Routine vaccination: 
• ActHIB, Hiberix, or Pentacel: 4-dose series at 2, 4, 
6, and 12–15 months.
• PedvaxHIB: 3-dose series at 2, 4, and 12–15 months.
Catch-up vaccination: 
• 1st dose at 7–11 months: Give 2nd dose at least 4 
weeks later d 3rd (final) dose at 12–15 onths or 
8 weeks after 2 d dose (whi hever is later).
• 1st dose at 12–14 months: Give 2nd (final) dose at 
least 8 w eks after 1st dose.
• 1st dose before 12 months and 2nd dose before 
15 months: Give 3rd (final) dose 8 weeks after 2nd 
dose.
• 2 doses of PedvaxHIB before 12 months: Give 3rd 
(final) dose at 12–59 months and t least 8 weeks 
after 2nd dose.
• Unvaccinated at 15–59 months: 1 dose.
• For other catch-up guidance, see Figure 2. 
Special Situation :
• Che otherapy r rad ati n tr atment 
12–59 months 
 ɱ Unvaccinated or only 1 dose before 12 months: 
Give 2 doses, 8 weeks apart
 ɱ 2 or more doses before 12 months: Give 1 dose, 
at least 8 weeks after previ us dose.
Doses given within 14 days of starting herapy or 
during therapy should be repeat d at least 3 months 
after therapy completion.
• Hematopoietic stem cell transplant (HSCT)
• 3-dose series with doses 4 weeks apart starting 6 to 
12 months after successful transplant (regardless of 
Hib vaccination history).
• Anatomic or functional asplenia (including sickle 
cell dis ase)
12–59 months
 ɱ Unvaccinated or only 1 dose before 12 months: 
Give 2 doses, 8 weeks ap rt.
 ɱ 2 or more doses before 12 months: Giv  1 dose, 
at least 8 weeks after pr vious dose.
Unimmunized* persons 5 years or older
 ɱ Give 1 dose
• Elective splenectomy
Unimmunized* persons 15 months or older




 ɱ Unvaccinated or only 1 dose before 12 
months: Give 2 doses 8 weeks apart.
 ɱ 2 or more doses before 12 months: Give 1 
dose, at least 8 weeks after previous dose.
Unimmunized* persons 5–18 years
 ɱ Give 1 dose
• Immunogl bulin eficiency, arly component 
complement deficiency
12–59 months
 ɱ U vaccinated or only 1 dose before 12 
months: Give 2 doses, 8 weeks apart.
 ɱ 2 or more doses before 12 months: Give 1 
dose, at least 8 we ks after previous dose.
*Unimmunized = Less than routine series (through 14 
months) OR no do s (14 months or older)
5.  Pneumococcal vaccines. (minimum age: 6 weeks 
[PCV13], 2 years [PPSV23])
Routine vaccination with PCV13:
• 4-dose series at 2, 4, 6, and 12–15 months.
Catch-up vaccination with PCV13:
• 1 dose for healthy children aged 24–59 months 
with any incomplete* PCV13 schedule
• For other catch-up guidance, see Figure 2.
Special situations: High-risk conditions: 
Administer PCV13 doses before PPSV23 if 
possible.
Chronic heart disease (particularly cyanotic 
congenital heart disease and cardiac failure); 
chronic lung disease (including asthma treated 
with high-dose, oral, corticosteroids); diabetes 
mellitus:
Age 2–5 years:
• Any incomplete* schedules with:
 ɱ 3 PCV13 doses: 1 dose of PCV13 (at least 8 
w eks af r any prior PCV13 dose).
 ɱ <3 PCV13 doses: 2 doses of PCV13, 8 weeks 
after the most recent dose and given 8 weeks 
apart.
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose). 
Age 6-18 years:
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose).
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
Cerebrospinal fluid leak; cochlear impl nt:
Age 2–5 years:
• Any incomplete* schedules with:
 ɱ 3 PCV13 doses: 1 dose of PCV13 (at least 8 
weeks after any prior PCV13 dose).
 ɱ <3 PCV13 doses: 2 doses of PCV13, 8 weeks 
after the most recent dose and given 8 weeks 
apart.
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose). 
Age 6–18 years:
• No history of either PCV13 or PPSV23: 1 dose of 
PCV13, 1 dose of PPSV23 at least 8 weeks later.
• Any PCV13 but no PPSV23: 1 dose of PPSV23 at 
least 8 weeks after he mo t ecent dose of PCV13
• PPSV23 but no PCV13: 1 dose of PCV13 at least 8 
weeks after the most recent dose of PPSV23.
Sickle cell disease and other hemoglobinopathies; 
anatomic or functional asplenia; congenital 
or acquired immunodeficiency; HIV infection; 
chronic renal failure; nephrotic syndrome; 
malignant neoplasms, leukemias, lymphomas, 
Hodgkin disease, and other diseases associated 
with treatment with immu osuppressive drugs 
or radiation therapy; solid organ transplantation; 
multiple myeloma:
Age 2–5 years:
• Any incomplete* schedules with:
 ɱ 3 PCV13 doses: 1 dose of PCV13 (at least 8 
weeks after any prior PCV13 dose).
 ɱ <3 PCV13 doses: 2 doses of PCV13, 8 weeks 
after the most recent dose and given 8 weeks 
apart.
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose) and a 2nd dose 
of PPSV23 5 years later.
Age 6–18 years:
• No history of either PCV13 or PPSV23: 1 dose of 
PCV13, 2 doses of PPSV23 (1st dose of PPSV23 
administered 8 weeks after PCV13 and 2nd dose of 
PPSV23 administered at least 5 years after the 1st 
dose of PPSV23).
• Any PCV13 but no PPSV23: 2 doses of PPSV23 (1st 
dose of PPSV23 to be given 8 weeks after  the most 
recent dose of PCV13 and 2nd dose of PPSV23 
administered at least 5 years after the 1st dose of 
PPSV23).
4.  Haemophilus influenzae type b (Hib) vaccine. 
(minimum age: 6 weeks) 
Routine vaccination: 
• ActHIB, Hiberix, or Pentacel: 4-dose series at 2, 4, 
6, and 12–15 months.
• PedvaxHIB: 3-dose series at 2, 4, and 12–15 months.
Catch-up vaccination: 
• 1st dose at 7–11 months: Give 2nd dose at least 4 
weeks later and 3rd (final) dose at 12–15 months or 
8 weeks after 2nd dose (whichever is later).
• 1st dose at 12–14 months: Give 2nd (final) dose at 
least 8 weeks after 1st dose.
• 1st dose before 12 months and 2nd dose before 
15 months: Give 3rd (final) dose 8 weeks after 2nd 
dose.
• 2 doses of PedvaxHIB before 12 months: Give 3rd 
(final) dose at 12–59 months and at least 8 weeks 
after 2nd dose.
• Unvaccinated at 15–59 months: 1 dose.
• For other catch-up guidance, see Figure 2. 
Special Situations:
• Chemotherapy or radiation treatment 
12–59 months 
 ɱ Unvaccinated or only 1 dose before 12 months: 
Give 2 doses, 8 weeks apart
 ɱ 2 or more doses before 12 months: Give 1 dose, 
at least 8 weeks after previous dose.
Doses given within 14 days of starting therapy or 
during therapy should be repeated at least 3 months 
after therapy completion.
• Hematopoietic stem cell transplant (HSCT)
• 3-dose series with doses 4 weeks apart starting 6 to 
12 months after successful transplant (regardless of 
Hib vaccination history).
• Anatomic or functional asplenia (including sickle 
cell disease)
12–59 months
 ɱ Unvaccinated or only 1 dose before 12 months: 
Give 2 doses, 8 weeks apart.
 ɱ 2 or more doses before 12 months: Give 1 dose, 
at least 8 weeks after previous dose.
Unimmunized* persons 5 years or older
 ɱ Give 1 dose
• Elective splenectomy
Unimmunized* persons 15 months or older




 ɱ Unvaccinated or only 1 dose before 12 
months: Give 2 doses 8 weeks apart.
 ɱ 2 or more doses before 12 months: Give 1 
dose, at least 8 weeks after previous dose.
Unimmunized* persons 5–18 years
 ɱ Give 1 dose
• Immunoglobulin deficiency, early component 
complement deficiency
12–59 months
 ɱ Unvaccinated or only 1 dose before 12 
months: Give 2 doses, 8 weeks apart.
 ɱ 2 or more doses before 12 months: Give 1 
dose, at least 8 weeks after previous dose.
*Unimmunized = Less than routine series (through 14 
months) OR no doses (14 months or older)
5.  Pneumococcal vaccines (minimum age: 6 weeks 
[PCV13], 2 years [PPSV23])
Routine vaccination with PCV13:
• 4-dose series at 2, 4, 6, and 12–15 months.
Catch-up vaccination with PCV13:
• 1 dose for healthy children aged 24–59 months 
with any incomplete* PCV13 schedule
• For other catch-up guidance, see Figure 2.
Special situations: High-risk conditions: 
Administer PCV13 doses before PPSV23 if 
possible.
Chronic heart disease (particularly cyanotic 
congenital heart disease and cardiac failure); 
chronic lung disease (including asthma treated 
with high-dose, oral, corticosteroids); diabetes 
mellitus:
Age 2–5 years:
• Any incomplete* schedules with:
 ɱ 3 PCV13 doses: 1 dose of PCV13 (at least 8 
weeks after any prior PCV13 dose).
 ɱ <3 PCV13 oses: 2 doses of PCV13, 8 weeks
after the most recent dose and given 8 w eks 
apart.
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose). 
Age 6-18 years:
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose).
For further guidance on the use of the vaccines mentioned bel w, se : www.cdc.gov/vaccines/hcp/acip-recs/index.html.
Cerebrospinal fluid leak; cochlear implant:
Age 2–5 years:
• Any incomplete* schedules with:
 ɱ 3 PCV13 doses: 1 dose of PCV13 (at least 8 
weeks after any prior PCV13 dose).
 ɱ <3 PCV13 doses: 2 doses of PCV13, 8 weeks 
after the most recent dose and given 8 weeks 
apart.
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose). 
Age 6–18 years:
• No history of either PCV13 or PPSV23: 1 dose of 
PCV13, 1 dose of PPSV23 at least 8 weeks later.
• Any PCV13 but no PPSV23: 1 dose of PPSV23 at 
least 8 weeks after the most recent dose of PCV13
• PPSV23 but no PCV13: 1 dose of PCV13 at least 8 
weeks after the most recent dose of PPSV23.
Sickle cell disease and other hemoglobinopathies; 
anatomic or functional asplenia; congenital 
or acquired immunodeficiency; HIV infection; 
chronic renal failure; nephrotic syndrome; 
malignant neoplasms, leukemias, lymphomas, 
Hodgkin disease, and other diseases associated 
with treatment with immunosuppressive drugs 
or radiation therapy; solid organ transplantation; 
multiple yeloma:
Age 2–5 years:
• Any incomplete* schedules with:
 ɱ 3 PCV13 dose : 1 dose of PCV13 (at least 8 
weeks aft r any prior PCV13 dose).
 ɱ <3 PCV13 doses: 2 doses of PCV13, 8 weeks 
after the most recent dose and given 8 weeks 
apart.
• N  history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose) and a 2nd dose 
of PPSV23 5 years later.
Age 6–18 years:
• No history f ither PCV13 or PPSV23: 1 dos  of 
PCV13, 2 doses of PPSV23 (1st dos  of PPSV23 
administered 8 weeks after PCV13 and 2nd dose of 
PPSV23 administered at least 5 years after the 1st 
dose of PPSV23).
• Any PCV13 but no PPSV23: 2 doses of PPSV23 (1st 
dose of PPSV23 to be given 8 weeks after  the most 
recent dose of PCV13 and 2nd dose of PPSV23 
administered at least 5 years after the 1st dose of 
PPSV23).For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
• PPSV23 but no PCV13: 1 dose of PCV13 at least 8 
weeks after the most recent PPSV23 dose and a 2nd 
dose of PPSV23 to be given 5 years after the 1st dose 
of PPSV23 and at least 8 weeks after a dose of PCV13.
Chronic liver disease, alcoholism:
Age 6–18 years:
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose).
*Incomplete schedules are any schedules where 
PCV13 doses have not been completed according to 
ACIP recommended catch-up schedules. The total 
number and timing of doses for complete PCV13 
series are dictated by the age at first vaccination. See 
Tables 8 and 9 in the ACIP pneumococcal vaccine 
recommendations (www.cdc.gov/mmwr/pdf/rr/
rr5911.pdf ) for complete schedule details.
6.  Inactiva d poli vi us vaccine (IPV). (minimum 
age: 6 weeks)
Routine vaccination:
• 4-dose series at ages 2, 4, 6–18 months, and 4–6 years. 
Administer the final dose on or after the 4th birthday 
and at least 6 months after the previous dose.
Catch-up vacci ation:
• In the first 6 months of life, use minimum ages and 
intervals only for travel to a polio-endemic region or 
during an outbreak.
• If 4 or more doses were given before the 4th birthday, 
give 1 more dose at age 4–6 years and at least 6 
months after the previous dose.
• A 4th dose is not necessary if the 3rd dose was given 
on or after the 4th birthday and at least 6 months 
after the previous dose.
• IPV is not routinely recommended for U.S. residents 
18 years and older.
Series Containing Oral Polio Vaccine (OPV), either 
mixed OPV-IPV or OPV-only series:
• Total number of doses needed to complete the series 
is the same as that recommended for the U.S. IPV 
schedule. See www.cdc.gov/mmwr/volumes/66/wr/
mm6601a6.htm?s_cid=mm6601a6_w. 
• Only trivalent OPV (tOPV) counts toward the 
U.S. vaccination requirements. For guidance to 
assess doses documented as “OPV” see www.
cdc.gov/mmwr/volumes/66/wr/mm6606a7.
htm?s_cid=mm6606a7_w.
• For other catch-up guidance, see Figure 2.
7.  Influenz  vaccines. (minimum age: 6 months)
Routine vaccination:
• Administer an age-appropriate formulation and 
dose of influenza vaccine annually.
 ɱ Children 6 months–8 years who did not 
receive at least 2 doses f influenz  vaccine 
before July 1, 2017 should receive 2 doses 
separated by at least 4 weeks. 
 ɱ Persons 9 years and older 1 dose
• Live ttenuated influenza vaccine (LAIV) not 
recommended for the 2017–18 season. 
• For additional guidance, see the 2017–18 ACIP 
influenza vaccine recommendations (MMWR 
August 25, 2017;66(2):1-20: www.cdc.gov/mmwr/
volumes/66/rr/pdfs/rr6602.pdf). 
(For the 2018–19 season, see the 2018–19 ACIP 
influenza vaccine recommendations.)
8.  Measles, mumps, and rubella (MMR) vaccine.  
(minimum age: 12 months for routine vaccination)
Routine vaccination:
• 2-dose seri s at 12– 5 months and 4–6 years.
• The 2 d dose may be giv n as early as 4 weeks after 
the 1st dose.
Catch-up vaccination:
• Unvaccinated children and adolescents: 2 doses at 
least 4 weeks apart.
International travel:
• Infants 6–11 months: 1 dose before departure. 
Revaccinate with 2 doses at 12–15 months (12 
months for children in high-risk areas) and 2nd dose 
as early as 4 weeks later.
• Unvaccinated children 12 months and older:  
2 doses at least 4 weeks apart before departure.
Mumps outbreak:
• Persons ≥12 months who previously received 
≤2 doses of mumps-containing vaccine and are 
identified by public health authorities to be at 
increased risk during a mumps outbreak should 
receive a dose of mumps-virus containing vaccine. 
9.  Varicella (VAR) vaccine.  (minimum age: 12 months)
Routine vaccination:
• 2-dose series: 12–15 months and 4–6 years.
• The 2nd dose may be given as early as 3 months 
after the 1st dose (a dose given after a 4-week 
interval may be counted).
Catch-up vaccination:
• Ensure persons 7–18 years without evidence of 
immunity (see MMWR 2007;56[No. RR-4], at  
www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have 2 
doses of varicella vaccine:
 ɱ Ages 7–12: routine interval 3 months  
(minimum interval: 4 weeks).
 ɱ Ages 13 and older: minimum interval 4 weeks.
10.  Hepatitis A (HepA) vaccine. (minimum age: 12 
months)
Routine vaccination:
• 2 doses, separated by 6-18 months, between the 
1st and 2nd birthdays. (A series begun before the 
2nd birthday should be completed even if the child 
turns 2 before the second dose is given.)
Catch-up vaccination:
• Anyone 2 years of age or older may receive HepA 
vaccine if desired.  Minimum interval between 
doses is 6 months.
Special populations:  
Previously unvaccinated persons who should be 
vaccinated: 
• Persons traveling to or working in countries with 
high or intermediate endemicity 
• Men who have sex with men 
• Users of injection and non-injection drugs  
• Persons who work with hepatitis A virus in a 
research laboratory or with non-human primates 
• Persons with clotting-factor disorders  
• Persons with chronic liver disease
• Persons who anticipate close, personal contact 
(e.g., household or regular babysitting) with an 
international adoptee during the first 60 days after 
arrival in the United States from a country with high 
or intermediate endemicity (administer the 1st dose 
as soon as the adoption is planned—ideally at least 
2 weeks before the adoptee’s arrival).
11.  Serogroup A, C, W, Y meningococcal vaccines. 
(Minimum age: 2 months [Menveo], 9 months 
[Menactra].
Routine:
• 2-dose series: 11-12 years and 16 years.
Catch-Up:
• Age 13-15 years: 1 dose now and booster at age 
16-18 years. Minimum interval 8 weeks.
• Age 16-18 years: 1 dose. 
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
• PPSV23 but no PCV13: 1 dose of PCV13 at least 8 
weeks after the most recent PPSV23 dose and a 2nd 
dose of PPSV23 to be given 5 years after the 1st dose 
of PPSV23 and at least 8 weeks after a dose of PCV13.
Chronic liver disease, alcoholism:
Age 6–18 years:
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose).
*Incomplete schedules are any schedules where 
PCV13 doses hav  not been completed ac ording to 
ACIP recommended catch-up schedules. The total 
number nd timing of doses for complete PCV13 
series are dictated by the age at first vaccination. See 
Tables 8 and 9 in the ACIP pneumococcal vac ine 
recommendations (www.cdc.gov/mmwr/ df/rr/
rr5911.pdf ) for complete schedule details.
6.  Inactivated poliovirus vaccine (IPV). (minimum 
age: 6 weeks)
Routine vaccination:
• 4-dose se ies at ages 2, 4, 6–18 months, and 4–6 years. 
Administer the final d se on or aft r the 4th birth ay 
and at least 6 months after the previous dose.
Catch-up vaccination:
• In t e first 6 mo th  of life, use minimum ages and 
intervals o ly for travel to a polio-endemic region or 
durin  an outb eak.
• If 4 or more doses were given before the 4th birthday, 
give 1 more dose at age 4–6 years and at least 6 
months after he previous dose.
• A 4th dose is not necessary if the 3rd dose was given 
on or after the 4th birthday and at least 6 m nths 
after the previous dose.
• IPV is not routinely recommended for U.S. residents 
18 years and older.
Series Containing Oral Polio Vaccine (OPV), either 
mixed OPV-IPV or OPV-only series:
• Total number of doses n eded to complete the series 
is th  same as that recommended for the U.S. IPV 
schedule. See www.cdc.gov/mmwr/volumes/66/wr/
mm6601a6.htm?s_cid=mm6601a6_w. 
• Only trivalent OPV (tOPV) counts toward the 
U.S. vaccination requirements. For guidance to 
assess doses documented as “OPV” see www.
cdc.gov/mmwr/volumes/66/wr/mm6606a7.
htm?s_cid=mm6606a7_w.
• For other catch-up guidance, see Figure 2.
7.  Influenza vaccines. (minimum age: 6 months)
Routin  vacci ation:
• Administer an age-appropriate formulation and 
dose of influenza vaccine annually.
 ɱ Children 6 months–8 years who did not 
receive at least 2 doses of influenza vaccine 
before July 1, 2017 should receive 2 doses 
separated by at least 4 weeks. 
 ɱ P rsons 9 years an  lder 1 dose
• Live tt nuated influ nza vaccine (LAIV) not 
recommended for the 2017–18 season. 
• For additional guidance, see the 2017–18 ACIP 
influenza vaccine recommendations (MMWR 
August 25, 2017;66(2):1-20: www.cdc.gov/mmwr/
volumes/66/rr/pdfs/rr6602.pdf). 
(For the 2018–19 season, see the 2018–19 ACIP 
influenza vaccine recommendations.)
8.  Measles, mumps, and rubella (MMR) vaccine.  
(minimum age: 12 months for routine vaccination)
Routine vaccination:
• 2-dose series at 12–15 months and 4–6 years.
• The 2nd dose may be given as early as 4 weeks after 
the 1st dose.
Catch-up vaccination:
• Unvaccinated children and adolescents: 2 doses at 
least 4 weeks apart.
International travel:
• Infants 6–11 months: 1 dose before departure. 
Revaccinate with 2 doses at 12–15 months (12 
months for children in high-risk areas) and 2nd dose 
as early as 4 weeks later.
• Unvaccinated children 12 months and older:  
2 doses at least 4 weeks apart before departure.
Mumps outbreak:
• Persons ≥12 months who previously received 
≤2 doses of mumps-containing vaccine and are 
identified by public health authorities to be at 
increased risk during a mumps outbreak should 
receive a dose of mumps-virus containing vaccine. 
9.  Varicella (VAR) vaccine.  (minimum age: 12 months)
Routine vaccination:
• 2-dose series: 12–15 months and 4–6 years.
• The 2nd dose may be given as early as 3 months 
after the 1st dose (a dose given after a 4-week 
interval may be counted).
Catch-up vacci ation:
• Ensure persons 7–18 years without evidence of 
immunity (see MMWR 2007;56[No. RR-4], at  
www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have 2 
doses of varicella vaccine:
 ɱ Ages 7–12: routine interval 3 months  
(minimum interval: 4 weeks).
 ɱ Ages 13 and older: minimum interval 4 weeks.
10.  Hepatitis A (HepA) vaccine. (minimum age: 12 
months)
Routine vaccination:
• 2 doses, separated by 6-18 months, between the 
1st and 2nd birthdays. (A series begun before the 
2nd birthday should be completed even if the child 
turns 2 before the second dose is given.)
Catch-up vaccination:
• Anyone 2 years of age or older may receive HepA 
vaccine if desired.  Minimum interval between 
doses is 6 months.
Special populations:  
Previously unvaccinated persons who should be 
vaccinated: 
• Persons traveling to r working in countries with 
high or intermediate endemicity 
• Men who have sex with men 
• Users of injection and non-injection drugs  
• Persons who work with hepatitis A virus in a 
research laboratory or with non-human primates 
• Persons with clotting-factor disorders  
• Persons with chronic liver disease
• Persons who anticipate close, personal contact 
(e.g., household or regular babysitting) with an 
international adoptee during the first 60 days after 
arrival in the United States from a country with high 
or intermediate endemicity (administer the 1st dose 
as soon as the adoption is planned—ideally at least 
2 weeks before the adoptee’s arrival).
11.  Serogroup A, C, W, Y meningococcal vaccines. 
(Minimum age: 2 months [Menveo], 9 months 
[Menactra].
Routine:
• 2-dose series: 11-12 years and 16 years.
Catch-Up:
• Age 13-15 years: 1 dose now and booster at age 
16-18 years. Minimum interval 8 weeks.
• Age 16-18 years: 1 dose. 
For further guida ce on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
• PPSV23 but no PCV13: 1 dose of PCV13 at least 8 
weeks after the most recent PPSV23 dose and a 2nd 
dose of PPSV23 to be given 5 years after the 1st dose 
of PPSV23 and at least 8 weeks after a dose of PCV13.
Chronic liver disease, lcoholism:
Age 6–18 years:
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose).
*Incomplete schedules are any schedules where 
PCV13 doses have not been completed according to 
ACIP recommended catch-up schedules. The total 
number and timing of doses for complete PCV13 
series are dictated by the age at first vaccination. See 
Tables 8 and 9 in the ACIP pneumococcal vaccine 
recommendations (www.cdc.gov/mmwr/pdf/rr/
rr5911.pdf ) for complete schedule details.
6.  Inactivated poliovirus vaccine (IP ). (minimum 
age: 6 we ks)
Routine vaccination:
• 4-dose series at ages 2, 4, 6–18 months, and 4–6 years. 
Administer the final dose on or aft r the 4th birthday 
and at least 6 months after the previous dose.
Catch-up vaccination:
• In the first 6 months of life, use minimum ages and 
intervals o ly for travel to a polio-endemic region or 
during an outbreak.
• If 4 or more doses were given before the 4th birthday, 
give 1 more dose at age 4–6 years and at least 6 
months after the previous dose.
• A 4th dose is not necessary if the 3rd dose was given 
on or after the 4th birthday and at least 6 months 
after the previous dose.
• IPV is not routinely recommended for U.S. residents 
18 years and older.
Series Containing Oral Polio Vaccine (OPV), either 
mixed OPV-IPV or OPV-only series:
• Total number of doses needed to complete the series 
is the same as that recommended for the U.S. IPV 
schedule. See www.cdc.gov/mmwr/volumes/66/wr/
mm6601a6.htm?s_cid=mm6601a6_w. 
• Only trivalent OPV (tOPV) counts toward the 
U.S. vaccination requirements. For guidance to 
assess doses documented as “OPV” see www.
cdc.gov/mmwr/volumes/66/wr/mm6606a7.
htm?s_cid=mm6606a7_w.
• For other catch-up guidance, see Figure 2.
7.  Influenza vaccines. (minimum age: 6 months)
Routine vaccination:
• Administer an age-appropriate formulation and 
dose of influenza vaccine annually.
 ɱ Children 6 months–8 years who did not 
receive at least 2 doses of influenza vaccine 
before July 1, 2017 should receive 2 doses 
separated by at least 4 weeks. 
 ɱ Persons 9 years and older 1 dose
• Live attenuat d influ nza vaccine (LAIV) not 
recommended for the 2017–18 season. 
• For additional guidance, see the 2017–18 ACIP 
influenza vaccine recommendations (MMWR 
August 25, 2017;66(2):1-20: www.cdc.gov/mmwr/
volumes/66/rr/pdfs/rr6602.pdf). 
(For the 2018–19 season, see the 2018–19 ACIP 
influenza vaccine recommendations.)
8.  Measles, mumps, and rubella (MMR) vaccine.  
(minimum age: 12 months for routine vaccination)
Routine vaccination:
• 2-dose series at 12–15 months and 4–6 years.
• The 2nd dose may be given as early as 4 weeks after 
the 1st dose.
Catch-up vaccination:
• Unvaccinated children and adolescents: 2 doses at 
least 4 weeks apart.
International travel:
• Infants 6–11 months: 1 dose before departure. 
Revaccinate with 2 doses at 12–15 months (12 
months for children in high-risk areas) and 2nd dose 
as early as 4 weeks later.
• Unvaccinated children 12 months and older:  
2 doses at least 4 weeks apart before departure.
Mumps outbreak:
• Persons ≥12 months who previously received 
≤2 doses of mumps-containing vaccine and are 
identified by public health authorities to be at 
increased risk during a mumps outbreak should 
receive a dose of mumps-virus containing vaccine. 
9.  Varicella (VAR) vaccine.  (minimum age: 12 months)
Routine vaccination:
• 2-dose series: 12–15 months and 4–6 years.
• The 2nd dose may be given as early as 3 months 
after the 1st dose (a dose given after a 4-week 
interval may be counted).
Catch-up vaccination:
• Ensure persons 7–18 years without evidence of 
immunity (see MMWR 2007;56[No. RR-4], at  
www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have 2 
doses of varicella vaccine:
 ɱ Ages 7–12: routine interval 3 months  
(minimum interval: 4 weeks).
 ɱ Ages 13 and older: minimum interval 4 weeks.
10.  Hepatitis A (HepA) vaccine. (minimum age: 12 
months)
Routine vaccination:
• 2 doses, separated by 6-18 months, between the 
1st and 2nd birthdays. (A series begun before the 
2nd birthday should be completed even if the child 
turns 2 before the second dose is given.)
Catch-up vaccination:
• Anyone 2 years of age or older may receive HepA 
vaccine if desired.  Minimum interval between 
doses is 6 months.
Special populations:  
Previously unvaccinated persons who should be 
vaccinated: 
• Persons traveling to or working in countries with 
high or intermediate endemicity 
• Men who have sex with men 
• Users of injection and non-injection drugs  
• Persons who work with hepatitis A virus in a 
research laboratory or with non-human primates 
• Persons with clotting-factor disorders  
• Persons with chronic liver disease
• Persons who anticipate close, personal contact 
(e.g., household or regular babysitting) with an 
international adoptee during the first 60 days after 
arrival in the United States from a country with high 
or intermediate endemicity (administer the 1st dose 
as soon as the adoption is planned—ideally at least 
2 weeks before the adoptee’s arrival).
11.  Serogroup A, C, W, Y meningococcal vaccines. 
(Minimum age: 2 months [Menveo], 9 months 
[Menactra].
Routine:
• 2-dose series: 11-12 years and 16 years.
Catch-Up:
• Age 13-15 years: 1 dose now and booster at age 
16-18 years. Minimum interval 8 weeks.
• Age 16-18 years: 1 dose. 
For further guida ce on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
• PPSV23 but no PCV13: 1 dose of PCV13 at least 8 
weeks after the most recent PPSV23 dose nd a 2nd 
dose of PPSV23 o be given 5 years after the 1s  dose 
of PPSV23 and at least 8 weeks after a dose of PCV13.
Chronic liver disease, alcoholism:
Age 6–18 years:
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose).
*Incomplete schedules are any schedules where 
PCV13 doses have not been completed according to 
ACIP recommended catch-up schedules. The total 
number and timing of doses for complete PCV13 
series are dictated by the age at first vaccination. See 
Tabl s 8 and 9 in the ACIP pneumococcal vaccine 
recommendations (www.cdc.gov/mmwr/pdf/rr/
rr59 1.pdf ) for complete sch dule details.
6.  Inactivated poliovirus vaccine (IPV). (minimum 
age: 6 weeks)
Routine vaccination:
• 4-dose series at ages 2, 4, 6–18 months, and 4–6 years. 
Administer the final dose o  or after the 4th birthday 
and at least 6 months after the previous dose.
Catc -up vaccinati n:
• In the first 6 months of life, use minimum ages and 
intervals only for travel to a polio-endemic regi  or 
during an outbr ak.
• If 4 or more doses were given before the 4th birthday, 
give 1 more dose at age 4–6 years and at least 6 
months after the previous dose.
• A 4th dose is not necessary if the 3rd dose was given 
on or after the 4th birthday and at least 6 months 
after the previous dose.
• IPV is not routinely recommended for U.S. residents 
18 years and older.
Series Containing Oral Polio Vaccine (OPV), either 
mixed OPV-IPV or OPV-only series:
• Total number of doses needed to complete the series 
is the sa e as that recommended for the U.S. IPV 
schedule. See www.cdc.gov/mmwr/volumes/66/wr/
mm6601a6.htm?s_cid=mm6601a6_w. 
• Only trivalent OPV (tOPV) counts toward the 
U.S. vaccination requirements. For guidance to 
assess doses documented as “OPV” see www.
cdc.gov/mmwr/volumes/66/wr/mm6606a7.
htm?s_cid=mm6606a7_w.
• For other catch-up guidance, see Figure 2.
7.  Influenza vaccines. (minimum age: 6 months)
Routine vaccination:
• Administer an age-appropriate formulation and 
dose of influenza vaccine annually.
 ɱ Children 6 months–8 years who did not 
receive at least 2 doses of influenza vaccine 
before July 1, 2017 should receive 2 doses 
separated by at least 4 weeks. 
 ɱ Persons 9 years and older 1 dose
• Live attenuated influenza vaccine (LAIV) not 
recommended for the 2017–18 season. 
• For additional guidance, see the 2017–18 ACIP 
influenza vaccine recommendations (MMWR 
August 25, 2017;66(2):1-20: www.cdc.gov/mmwr/
volumes/66/rr/pdfs/rr6602.pdf). 
(For the 2018–19 season, see the 2018–19 ACIP 
influenza vaccine recommendations.)
8.  Measles, mumps, and rubella (MMR) vaccine.  
( inimum age: 12 months f r routine vaccination)
Routine vaccination:
• 2-dose series at 12–15 months and 4–6 years.
• The 2nd dose may be given as early as 4 weeks after 
the 1st dose.
Catch-up vaccination:
• Unvaccinated children and adolescents: 2 doses at 
least 4 weeks apart.
International travel:
• In ants 6–11 month : 1 dose be ore departure. 
Revaccinate with 2 doses at 12–15 months (12 
months for children in high-risk areas) and 2nd dose 
as early as 4 weeks later.
• Unvac inated childr n 12 months and older:  
2 doses at least 4 weeks apart before departure.
Mumps outbreak:
• Persons ≥12 months who previously received 
≤2 doses of mumps-containing vaccine and are 
id ntified by public health authorities to be at 
increased risk during a m mps outbreak should 
receive a dose of mumps-virus containing v ccine. 
9.  Varicella (VAR) vaccine.  (minimum age: 12 months)
Routine vaccination:
• 2-dose series: 12–15 months and 4–6 years.
• The 2nd dose may be given as early as 3 months 
after the 1st dose (a dose given after a 4-week 
interval may be counted).
Catch-up vaccination:
• Ensure persons 7–18 years without evidence of 
immunity (see MMWR 2007;56[No. RR-4], at  
www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have 2 
doses of varicella vaccine:
 ɱ Ages 7–12: routine interval 3 months  
(minimum interval: 4 weeks).
 ɱ Ages 13 and older: minimum interval 4 weeks.
10.  Hepatitis A (HepA) vaccine. (minimum age: 12 
months)
Routine vaccination:
• 2 doses, separated by 6-18 months, between the 
1st and 2nd birthdays. (A series begun before the 
2nd birthday should be completed even if the child 
turns 2 before the second dose is given.)
Catch-up vaccination:
• Anyone 2 years of age or older may receive HepA 
vaccine if desired.  Minimum interval between 
doses is 6 months.
Special populations:  
Previously unvaccinated persons who should be 
vaccinated: 
• Persons traveling to or working in countries with 
high or intermediate endemicity 
• Men who have sex with men 
• Users of injection and non-injection drugs  
• Persons who work with hepatitis A virus in a 
research laboratory or with non-human primates 
• Persons with clotting-factor disorders  
• Persons with chronic liver disease
• Persons who anticipate close, personal cont ct 
(e.g., household or regular babysitting) with an 
international adoptee during the first 60 days after 
arrival in the Unit d St t s from a country with high 
or intermedi t  e demicity (administer the 1st dose 
as s on as the ad ption is planned—ideally at least 
2 eeks before the adoptee’s arrival).
11.  Serogroup A, C, W, Y meningococcal vaccines. 
(Minimum age: 2 months [Menveo], 9 months 
[Menactra].
Routine:
• 2-dose series: 11-12 years and 16 years.
Catch-Up:
• Age 13-15 years: 1 dose now and booster at age 
16-18 years. Minimum interval 8 weeks.
• Age 16-18 years:  dose. 
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
• PPSV23 but no PCV13: 1 dose of PCV13 at least 8 
weeks after the most recent PPSV23 dose and a 2nd 
dose of PPSV23 to be given 5 years after the 1st dose 
of PPSV23 and at least 8 weeks after a dose of PCV13.
Chronic liver disease, alcoholism:
Age 6–18 years:
• No history of PPSV23: 1 dose of PPSV23 (at least 8 
weeks after any prior PCV13 dose).
*Incomplete schedules ar  any schedules where 
PCV 3 doses have not bee  compl ted according to 
ACIP recomm nded catch-up schedules. The total 
number and timing of doses for complete PCV13 
series are dictated by the age at first vaccination. See 
Tables 8 and 9 in the ACIP pneumococcal vaccine 
recommendations (www.cdc.gov/mmwr/pdf/rr/
rr5911.pdf ) for complete schedule etails.
6.  Inactivated poliovirus vaccine (IPV). (minimum 
age: 6 weeks)
Routine vaccination:
• 4-dose series at ages 2, 4, 6–18 months, and 4–6 years. 
Administer the final dose on or after the 4th birthday 
and at l ast 6 months after the pr vious dos .
Catch-up accination:
• In the first 6 months of life, use ini um ages and 
intervals only for travel to a polio-endemic region or 
during an outbreak.
• If 4 or more doses were given before the 4th birthday, 
give 1 more dose at age 4–6 years and at least 6 
months after the previous dose.
• A 4th dose is not necessary if the 3rd dose was given 
on or after the 4th birthday and at least 6 months 
after the previous dose.
• IPV is not routinely recommended for U.S. residents 
18 years and older.
Series Containing Oral Polio Vaccine (OPV), either 
mixed OPV-IPV or OPV- nly series:
• Total number f doses needed to complete the series 
is the same as that recommended for the U.S. IPV 
sched le. See www.cdc.gov/mmwr/volumes/66/wr/
mm6601a6.htm?s_cid=mm6601a6_w. 
• Only trivalent OPV (tOPV) counts toward the 
U.S. vaccination requirements. For guidance to 
assess doses documented as “OPV” see www.
cdc.gov/mmwr/volumes/66/wr/mm6606a7.
htm?s_cid=mm6606a7_w.
• For other catch-up guidance, see Figure 2.
7.  Influenza vaccines. (minimum age: 6 months)
Routine vaccination:
• Administer an age-appropriate formulation and 
dose of influenza vaccine annually.
 ɱ hildren 6 months–8 years who id not 
receive at least 2 doses of influenza vaccine 
befor  July 1, 2017 should receive 2 doses 
separated by at least 4 weeks. 
 ɱ Persons 9 years and older 1 dose
• Live attenuated influenza vaccine (LAIV) not 
recommended for the 2017–18 season. 
• For additional guidance, see the 2017–18 ACIP 
influenza vaccine recommendations (MMWR 
August 25, 2017;66(2):1-20: www.cdc.gov/mmwr/
volumes/66/rr/pdfs/rr6602.pdf). 
(For the 2018–19 season, see the 2018–19 ACIP 
influenza vaccine recommendations.)
8.  Measles, mumps, and rubella (MMR) vaccine.  
(minimum age: 12 months for routine vaccination)
Rou in  vaccin tion:
• 2-dose series at 12–15 months and 4–6 years.
• The 2nd dose may be given as early as 4 weeks after 
the 1st dose.
Catch-up vaccination:
• Unvaccinated children and adolescents: 2 doses at 
least 4 weeks apart.
International travel:
• Infants 6–11 months: 1 dose before departure. 
Revaccinate with 2 doses t 12–15 months (12 
months for children in high-risk areas) and 2nd dose 
as early as 4 weeks later.
• Unvaccinated children 12 months and older:  
2 doses at least 4 weeks apart before departure.
Mumps outbreak:
• Pers s ≥12 mont  wh  previously received 
≤2 doses of mumps-containing vaccine nd re 
identified by public health authorities to be at 
increased risk during a mumps utbreak should 
receive a do e of mumps-virus containing vaccin . 
9.  Varicella (VAR) vaccine.  (minimum age: 12 months)
Routine vaccination:
• 2-dose series: 12–15 months and 4–6 years.
• The 2 d dose may b  given as early as 3 months 
after the 1s  dose (a dose given after a 4-week 
interval may be counted).
Catch-up vaccination:
• Ensure persons 7–18 years without evidence of 
immunity (see MMWR 2007;56[No. RR-4], at  
www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have 2 
doses of varicella vaccine:
 ɱ Ages 7–12: routine interval 3 months  
(minimum interval: 4 weeks).
 ɱ Ages 13 and older: minimum interval 4 weeks.
10.  Hepatitis A (HepA) vaccine. (minimum age: 12 
months)
Routine vaccination:
• 2 doses, separated by 6-18 months, between the 
1st and 2nd birthdays. (A series begun before the 
2nd birthday should be completed even if the child 
turns 2 before the second dose is given.)
Catch-up vaccination:
• Anyone 2 years of age or older may receive HepA 
vaccine if desired.  Minimum interval between 
doses is 6 months.
Special p pulations:  
Previously unvaccinated persons who should be 
vaccinated: 
• Persons traveling to or working in countries with 
high or intermediate endemicity 
• Men who have sex with men 
• Users of injection and non-injection drugs  
• Persons who work with hepatitis A virus in a 
research laboratory or with non-human primates 
• Persons with clotting-factor disorders  
• Persons with chronic liver di ase
• Persons who anticipat  close, personal co tact 
(e.g., househol or regular babysitting) with an 
internati nal doptee during first 60 days after 
arrival i  th  Unit d States from a country with high 
or intermediate endemicity (administer the 1st dose 
as soon as the adoption is planned—ideally at least 
2 weeks before the adoptee’s arrival).
11.  Serogroup A, C, W, Y meningococcal vaccines. 
( inimum age: 2 months [Menveo], 9 months 
[Me actra].
Routine:
• 2-dose series: 11-  years a d 16 years.
Catc -Up:
• Ag  3-15 y ars: 1 do e now and booster at age 
16-18 years. Minimum interval 8 weeks.
• Age 16-18 years: 1 ose. For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
CS270457-M
Special populations and situations: 
Anatomic or functional asplenia, sickle cell disease, 
HIV infection, persistent complement component 
deficiency (including eculizumab use):
• Menveo
 ɱ 1st dose at 8 weeks: 4-dose series at 2, 4, 6, and 12 
months.
 ɱ 1st dose at 7–23 months: 2 doses (2nd dose at 
least 12 weeks after the 1st dose and after the 1st 
birthday).
 ɱ 1st dose at 24 months or older: 2 doses at least 8 
weeks apart.
• Menactra
 ɱ Persistent complement component deficiency: 
 ʲ 9–23 months: 2 doses at least 12 weeks apart
 ʲ 24 months or older: 2 doses at least 8 weeks 
apart
 ɱ Anatomic or functional asplenia, sickle cell 
disease, or HIV infection: 
 ʲ 24 months or older: 2 doses at least 8 weeks 
apart. 
 ʲ Menactr  must be administered at least 4 
weeks after completion of PCV13 series.
Children who travel to or live in countries where 
meningo o cal disease is hype endemic or 
epi emic, including countries in the African 
meningitis belt or during the Hajj, or exposure to an 
outbreak attributabl  to a vaccine serogroup:
• Children <24 months of age:
 ɱ Menveo (2-23 months):
 ʲ 1st dos  at 8 weeks: 4-dose series at 2, 4, 6, and 
12 months.
 ʲ 1st dose at 7-23 months: 2 doses (2nd dose at 
least 12 weeks after the 1st dose and after the 
1st birthday).
 ɱ Menactra (9-23 months): 
 ʲ 2 doses (2nd dose at least 12 weeks after the 
1st dose. 2nd dose may be administered as 
early as 8 weeks after the 1st dose in travelers).
• Children 2 years or older: 1 dose of Menveo or 
Menactra.
Note: Menactra should be given either before or at 
the same time as DTaP. For MenACWY booster dose 
recommendations for groups listed under “Special 
populations and situations” above, and additional 
meningococcal vaccination information, see 
meningococcal MMWR publications at: www.cdc.gov/
vaccines/hcp/acip-recs/vacc-specific/mening.html.
12.  Serogroup B meningococcal vaccines (minimum 
age: 10 years [Bexsero, Trumenba].
Clinical discretion: Adolescents not at increased 
risk for meningococcal B infection who want 
MenB vaccine.
MenB vaccines may be given at clinical discretio  to 
adolescen s 16–23 years (preferred age 16–18 years) 
who are not at increased risk. 
• Bexsero: 2 os s at l ast 1 month apart.
• Trume ba: 2 doses at lea t 6 months ap rt. If the 
2nd dose is given arlier tha  6 months, give a 3rd 
dose at least 4 months after the 2nd. 
Special populations and situations:
Anatomic or functional asplenia, sickle cell 
disease, persistent complement component 
deficiency (including eculizumab use), serogroup 
B meningococcal disease outbreak
• Bexsero: 2-dose series at least 1 month apart.
• Trumenba: 3-dose series at 0, 1-2, and 6 months.
Note: Bexsero and Trumenba are not 
interchangeable.
For additional meningococcal vaccination 
information, see meningococcal MMWR publications 
at: www.cdc.gov/vaccines/hcp/acip-recs/vacc-
specific/mening.html.
13.  Tetanus, diphtheria, and acellular pertussis 
(Tdap) vaccine. (minimum age: 11 years for 
routine vaccinations, 7 years for catch-up 
vaccination)
Routine vaccination: 
• Adolescents 11–12 years of age: 1 dose.
• Pregnant adolescents: 1 dose during each 
pregnancy (preferably during the early part of 
gestational weeks 27–36). 
• Tdap may be administered regardless of the 
interval since the last tetanus- and diphtheria-
toxoid-containing vaccine.
Catch-up vaccination:
• Adolescents 13–18 who have not received Tdap: 
1 dose, followed by a Td booster every 10 years.
• Persons aged 7–18 years not fully immunized 
with DTaP:  1 dose of Tdap as part of the catch-up 
series (preferably the first dose). If additional doses 
are needed, use Td.
• Children 7–10 years who receive Tdap 
inadvertently or as part of the catch-up series may 
receive the routine Tdap dose at 11–12 years.
• DTaP inadvertently given after the 7th birthday: 
 ɱ Child 7–10: DTaP may count as part of 
catch-up series. Routine Tdap dose at 11-12 
may be given.
 ɱ Adolescent 11–18: Count dose of DTaP as the 
adolescent Tdap booster. 
• For other catch-up guidance, see Figure 2.
14.  Human papillomavirus (HPV) vaccine (minimum 
age: 9 years)
Routine and catch-up vaccination:
• Routine vaccination for all adolescents at 11–12 
years (can start at age 9) and through age 18 if 
not previously adequately vaccinated. Number of 
doses dependent on age at initial vaccination: 
 ɱ Age 9–14 years at initiation: 2-dose series 
at 0 and 6–12 months. Minimum interval: 5 
months (repeat a dose given too soon at least 
12 weeks after the invalid dose and at least 5 
months after the 1st dose).
 ɱ Age 15 years or older at initiation: 3-dose 
series at 0, 1–2 months, and 6 months. 
Minimum intervals: 4 weeks between 1st  and 
2nd dose; 12 weeks between 2nd  and 3rd 
dose; 5 months between 1st and 3rd dose 
(repeat dose(s) given too soon at or after the 
minimum interval since the most recent dose).
• Persons who have completed a valid series with 
any HPV vaccine do not need any additional doses. 
Special situations:
• History of sexual abuse or assault: Begin series at 
age 9 years.
• Immunocompromised* (including HIV) aged 
9–26 years: 3-dose series at 0, 1–2 months, and 6 
months.
• Pregnancy: Vaccination not recommended, 
but there is no evidence the vaccine is harmful. 
No intervention is needed for women who 
inadvertently received a dose of HPV vaccine 
while pregnant. Delay remaining doses until after 
pregnancy. Pregnancy testing not needed before 
vaccination.
*See MMWR, December 16, 2016;65(49):1405–1408, 
at www.cdc.gov/mmwr/volumes/65/wr/pdfs/
mm6549a5.pdf.For further guidan e on the use of the vaccines mentioned below, see: www. dc.gov vaccines/hcp/acip-recs/index.html.
CS270457-M
Special populations and situations: 
A atomic r functional asplenia, sickle cell disease, 
HIV infection, persistent complement compon nt 
deficien y (including eculizumab use):
• Menveo
 ɱ 1st do e at 8 weeks: 4-dose series at 2, 4, 6, and 12 
months.
 ɱ 1 t dose t 7–23 months: 2 doses (2nd dose at 
least 12 wee s after the 1st dose and after the 1st 
birthday).
 ɱ 1st dose at 24 months or older: 2 doses at least 8 
weeks apart.
• Menactra
 ɱ Persistent c mple ent comp ent deficien y: 
 ʲ 9–23 months: 2 doses at least 12 weeks apart
 ʲ 24 months or older: 2 doses at least 8 weeks 
apart
 ɱ Anatomic or functional asplenia, sickle cell 
disease, or HIV inf ction: 
 ʲ 24 months or older: 2 doses at least 8 weeks 
apart. 
 ʲ Menactra must be administered at least 4 
weeks after completion of PCV13 series.
Childr n who tr vel to or live in countries where 
meningococc l disease is hyperendemic or 
epidemic, including countries in the African 
meningitis belt or during the Hajj, or exposure to an 
outbreak attributable to a vaccine serogroup:
• Children <24 months of age:
 ɱ Menveo (2-23 months):
 ʲ 1st dose at 8 weeks: 4-dose series at 2, 4, 6, and 
12 months.
 ʲ 1st dose at 7-23 months: 2 doses (2nd dose at 
least 12 weeks after the 1st dose and after the 
1st birthday).
 ɱ Menactra (9-23 months): 
 ʲ 2 doses (2nd dose at least 12 weeks after the 
1st dose. 2nd dose may be administered as 
arl  as 8 weeks after the 1st dose in travelers).
• Children 2 years or older: 1 dose of Menv o or 
Menactra.
Not : Menactra sh uld be given either before or at 
the same time as DTaP. For MenACWY booster os  
recommen ations for groups listed under “Special 
populations and s tua ions” above, and addi ional 
men ngococcal vaccinatio  information, see 
meningococcal MMWR publications at: www.cdc.gov/
vaccin s/hcp/acip-recs/vacc-specifi /mening.html.
12.  Serogroup B meningococcal vaccines (minimum 
age: 10 years [Bexsero, Trumenba].
Clinical discretion: Adolescent  not at increased 
risk for men ngoc ccal B infection who want 
MenB vaccine.
MenB vaccines may be given at clinical discretion to 
adolescents 16–23 years (preferred age 16–18 years) 
who are not at increased risk. 
• Bexsero: 2 doses at least 1 month apart.
• Trumenba: 2 doses at least 6 months apart. If the 
2nd dose is given earlier than 6 months, give a 3rd 
dose at least 4 months after the 2nd. 
Special populations and situations:
Anatomic or functional asplenia, sickle cell 
disease, persistent complement component 
deficiency (including eculizumab use), serogroup 
B meningococcal disease outbreak
• Bexsero: 2-dose series at least 1 month apart.
• Trumenba: 3-dose series at 0, 1-2, and 6 months.
Note: Bexsero and Trumenba are not 
interchangeable.
For additional meningococcal vaccination 
information, see meningococcal MMWR publications 
at: www.cdc.gov/vaccines/hcp/acip-recs/vacc-
specific/mening.html.
13.  Tetanus, diphtheria, and acellular pertussis 
(Tdap) vaccine. (minimum age: 11 years for 
routine vaccinations, 7 years for catch-up 
vaccination)
Routine vaccination: 
• Adolescents 11–12 years of age: 1 dose.
• Pregnant adolescents: 1 dose during each 
pregnancy (preferably during the early part of 
gestational weeks 27–36). 
• Tdap may be administered regardless of the 
interval since the last tetanus- and diphtheria-
toxoid-containing vaccine.
Catch-up vaccination:
• Adolescents 13–18 who have not received Tdap: 
1 dose, followed by a Td booster every 10 years.
• Persons aged 7–18 years not fully immunized 
with DTaP:  1 dose of Tdap as part of the catch-up 
series (preferably the first dose). If additional doses 
are needed, use Td.
• Children 7–10 years who receive Tdap 
inadvertently or as part of the catch-up series may 
receive the routine Tdap dose at 11–12 years.
• DTaP inadvertently given after the 7th birthday: 
 ɱ Child 7–10: DTaP may count as part of 
catch-up series. Routine Tdap dose at 11-12 
may be given.
 ɱ Adolescent 11–18: Count dose of DTaP as the 
adolescent Tdap booster. 
• For other catch-up guidance, see Figure 2.
14.  Human papillomavirus (HPV) vaccine (minimum 
age: 9 years)
Routine and catch-up vaccination:
• Routine vaccination for all adolescents at 11–12 
years (can start at age 9) and through age 18 if 
not previously adequately vaccinated. Number of 
doses dependent on age at initial vaccination: 
 ɱ Age 9–14 years at initiation: 2-dose series 
at 0 and 6–12 months. Minimum interval: 5 
months (repeat a dose given too soon at least 
12 weeks after the invalid dose and at least 5 
months after the 1st dose).
 ɱ Age 15 years or older at initiation: 3-dose 
series at 0, 1–2 months, and 6 months. 
Minimum intervals: 4 weeks between 1st  and 
2nd dose; 12 weeks between 2nd  and 3rd 
dose; 5 months between 1st and 3rd dose 
(repeat dose(s) given too soon at or after the 
minimum interval since the most recent dose).
• Persons who have completed a valid series with 
any HPV vaccine do not need any additional doses. 
Special situations:
• History of sexual abuse or assault: Begin series at 
age 9 years.
• Immunocompromised* (including HIV) aged 
9–26 years: 3-dose series at 0, 1–2 months, and 6 
months.
• Pregnancy: Vaccination not recommended, 
but there is no evidence the vaccine is harmful. 
No intervention is needed for women who 
inadvertently received a dose of HPV vaccine 
while pregnant. Delay remaining doses until after 
pregnancy. Pregnancy testing not needed before 
vaccination.
*See MMWR, December 16, 2016;65(49):1405–1408, 
at www.cdc.gov/mmwr/volumes/65/wr/pdfs/
mm6549a5.pdf.
For further guidan e on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.
CS270457-M
Special populations and situa ions: 
A atomic r functional asplenia, sickle cell disease, 
HIV infection, persist nt complement comp n nt 
deficiency (including eculizumab use):
• Menveo
 ɱ 1st do e at 8 weeks: 4-dose series at 2, 4, 6, and 12 
months.
 ɱ 1 t dose t 7–23 months: 2 doses (2nd dose at
least 12 weeks fter the 1st dose and afte  the 1st 
birthday).
 ɱ 1st dose at 24 months or older: 2 doses at least 8 
weeks apart.
• Me actra
 ɱ Persistent c mple ent comp ent deficiency: 
 ʲ 9–23 months: 2 doses at least 12 weeks apart
 ʲ 24 months r older: 2 do es at least 8 we ks 
par
 ɱ Anatomic or functional a plenia, sickle cell 
disease, or HIV inf ct on: 
 ʲ 24 months or older: 2 doses at least 8 weeks 
apart. 
 ʲ Menactra must be administered at least 4 
weeks after completion of PCV13 series.
Children who travel to or live in countries where 
meningococcal disease is hyperendemic or 
epidemic, including countries in the African 
meningitis belt or during the Hajj, or exposure to an 
outbreak attributable to a vaccine serogroup:
• Children <24 months of age:
 ɱ Menveo (2-23 months):
 ʲ 1st dose at 8 weeks: 4-dose series at 2, 4, 6, and 
12 months.
 ʲ 1st dose at 7-23 months: 2 doses (2nd dose at 
least 12 weeks after the 1st dose and after the 
1st birthday).
 ɱ Menactra (9-23 months): 
 ʲ 2 doses (2nd dose at least 12 weeks after the 
1st dose. 2nd dose may be administered as 
early as 8 weeks after the 1st dose in travelers).
• Children 2 years or older: 1 dose of Menveo or 
Menactra.
Note: Menactra should be given either before or at 
the same time as DTaP. For MenACWY booster dose 
recommendations for groups listed under “Special 
populations and situations” above, and additional 
meningococcal vaccination information, see 
meningococcal MMWR publications at: www.cdc.gov/
vaccines/hcp/acip-recs/vacc-specific/mening.html.
12.  Ser group B meningococcal vaccines (minimum 
age: 10 y ars [Bexs ro, Trumenba].
Clinical discretion: Adolesce ts not at increased 
risk for men ngoc cca  B inf ction  wa t 
MenB vaccine.
MenB vaccines may be given at clinical discretion to 
adolescents 16–23 years (preferred age 16–18 years) 
who are not at increased risk. 
• Bexsero: 2 doses at least 1 month apart.
• Trumenba: 2 doses at least 6 months apart. If the 
2nd dose is given earlier than 6 months, give a 3rd 
dose at least 4 months after the 2nd. 
Special populations and situations:
Anatomic or functional asplenia, sickle cell 
disease, persistent complement component 
deficiency (including eculizumab use), serogroup 
B meningococcal disease outbreak
• Bexsero: 2-dose series at least 1 month apart.
• Trumenba: 3-dose series at 0, 1-2, and 6 months.
Note: B xsero and Trumenba are n t 
interchangeabl .
For additional meningococcal vaccination 
information, see meningococcal MMWR publications 
at: www.cdc.gov/vaccin s/hcp/acip-recs/vacc-
specific/mening.html.
13.  Teta us, diphtheria, and acellular pertussis 
(Tdap) va cin . (minimum age: 1  years for 
routine vaccinations, 7 years for catch-up 
vaccination)
Routi e vaccination: 
• Adolescents 11–12 years of age: 1 dose.
• Pregnant adolescents: 1 dose during each 
pregna cy (preferably during the early part of 
gestational weeks 27–36). 
• Tdap may be administered regardless of the 
interval since the last tetanus- and diphtheria-
toxoid-containing vaccine.
Catch-up vaccination:
• Adolescents 13–18 who have not received Tdap: 
1 dose, followed by a Td booster every 10 years.
• Persons aged 7–18 years not fully immunized 
with DTaP:  1 dose of Tdap as part of the catch-up 
series (preferably the first dose). If additional doses 
are needed, use Td.
• Children 7–10 years who receive Tdap 
inadvertently or as part of the catch-up series may 
receive the routine Tdap dose at 11–12 years.
• DTaP inadvertently given after the 7th birthday: 
 ɱ Child 7–10: DTaP may count as part of 
catch-up series. Routine Tdap dose at 11-12 
may be give .
 ɱ Adolescent 11–18: Count dose of DTaP as the 
adolescent Tdap booster. 
• For other catch-up guidance, see Figure 2.
14.  Human papillom virus (HPV) vaccine (minimum
age: 9 years)
Routine and c tch-up vaccination:
• Ro tine vaccination for all a lescents at 11–12 
years (can start at age 9) and through age 18 if 
not previously adequately vaccinated. Number of 
doses dependent on age at initial vaccina ion: 
 ɱ Age 9–14 years at initiation: 2-dose series 
at 0 and 6–12 months. Minimum interval: 5 
months (repeat a dose given too soon at least 
12 weeks after the invalid dose and at least 5 
months after the 1st dose).
 ɱ Age 15 years or older at initiation: 3-dose 
series at 0, 1–2 months, a d 6 months. 
Minimum intervals: 4 weeks between 1st  and 
2nd dose; 12 weeks between 2nd  and 3rd 
dose; 5 m nths between 1st and 3rd dose 
(repeat dose(s) given too soon at or after the 
mi imum interval since th  most recent dose).
• Persons who have ompleted a valid series with 
any HPV vaccine d  not need n  additional doses. 
Special situations:
• History of sexual abuse or assault: Begin series at 
age 9 y ars.
• Immunocompromised* (including HIV) ged 
9–26 y ars: 3-dose series at 0, 1–2 months, and 6 
months.
• Pregnancy: Vaccination not recommended, 
but there is no evidence the vaccine is harmful. 
No intervention is needed for women who 
inadvertently received a dose of HPV vaccine 
while pregnant. Delay r maining doses until after 
pregnancy. Pregnancy testing not needed before 
vaccination.
*See MMWR, December 16, 2016;65(49):1405–1408, 
at www.cdc.gov/mmwr/volumes/65/wr/pdfs/
mm6549a5.pdf.
For further guid nce on the use f the vaccines mentioned below, see: www.cdc.gov/vaccines/h p/acip-recs/index.html.
CS270457-M
Special p pulations and situations: 
Anatomic or functional asplenia, sickle cell dis ase, 
HIV infe tion, persistent co plement component 
deficiency (in lu ing eculizumab use):
• Menveo
 ɱ 1st dose at 8 weeks: 4-dose s rie t 2, 4, 6, and 12 
months.
 ɱ 1 t dose at 7–23 months: 2 doses (2nd dose at 
least 12 we ks after the 1st dose and after the 1st 
birthday).
 ɱ 1st dose at 24 months or older: 2 doses at least 8 
we ks apart.
• M nactra
 ɱ Persistent complement component deficiency: 
 ʲ 9–23 onths:  doses at least 12 weeks ap r
 ʲ 24 months or older: 2 d ses at least 8 weeks 
apart
 ɱ Anatomic or functional asplenia, sickle cell 
dis ase, or HIV infection: 
 ʲ 24 months or older: 2 doses t least 8 w eks 
apart. 
 ʲ Menactra must be administered at least 4 
weeks after completion of PCV13 series.
Childre  ho r v l to or live in countries where 
meningococcal disease is hyperendemic r 
epidemic, including countries in the Afric n 
meningitis belt or during the Hajj, or exposure to an 
outbreak attributable to a vaccine serogroup:
• Children <24 months of age:
 ɱ Menveo (2-23 months):
 ʲ 1st d se at 8 weeks: 4-dose series at 2, 4, 6, and 
12 months.
 ʲ 1st dose at 7-23 months: 2 doses (2nd dose at 
least 12 weeks after the 1st dose and after the 
1st birthday).
 ɱ Menactra (9-23 months): 
 ʲ 2 doses (2nd dose at least 12 weeks after the 
1st dose. 2nd dose may be administered as 
early as 8 weeks after the 1st dose in travelers).
• Children 2 years or older: 1 dose of Menveo or 
Menactra.
Note: Menactra should be given either before or at 
the same time as DTaP. For MenACWY booster dose 
recommendations for groups listed under “Special 
populations and situations” above, and additional 
meningococcal vaccination information, see 
meningococcal MMWR publications at: www.cdc.gov/
vaccines/hcp/acip-recs/vacc-sp cific/mening.html.
12.  Serogroup B meningococcal vaccines (minimum 
age: 10 years [Bexsero, T umenba].
Clinical discretion: Adol scent  not at increas d 
risk for me ingococc l B i f tion who want 
MenB v ccine.
MenB vaccines may be given at clinical discretion to 
adolescents 16–23 years (preferred age 16–18 years) 
who are not at increased risk. 
• Bexsero: 2 doses at least 1 month apart.
• Trumenba: 2 doses at least 6 months apart. If the 
2nd dose is given earlier than 6 months, give a 3rd 
dose at least 4 months after the 2nd. 
Special populations and situations:
Anatomic or functional asplenia, sickle cell 
disease, persistent complement component 
deficiency (including eculizumab use), serogroup 
B meningococcal disease outbreak
• Bexsero: 2-dose series at least 1 month apart.
• Trumenba: 3-dose series at 0, 1-2, and 6 months.
Not : Bexsero and Trumenba are not 
interchangeab e.
For additional meningococcal vaccination 
information, see meningococcal MMWR publications 
at: www.cdc.gov/vaccines/hcp/acip-recs/vacc-
specific/mening.html.
13.  Tetanus, diphtheria, and acellular p rtussis 
(Tdap) vaccine. (minimum age: 11 years for 
routine vaccinati s, 7 years for catch-up 
vaccination)
Routine vaccination: 
• Adolescents 11–12 years of age: 1 dose.
• Pregnant adolescents: 1 dose during each 
pregnancy (preferably during the early part of 
gestational weeks 27–36). 
• Tdap may be administered regardless of the 
interval since the last tetanus- and diphtheria-
toxoid-containing vaccine.
Catch-up vaccination:
• Adolescents 13–18 who have not eceiv d Tdap: 
1 dose, followed by a Td bo ster every 10 y ars.
• Persons aged 7–18 years not fully immunized 
with DTaP:  1 ose of Tdap as part of the c tch-up 
series (prefe ably the first dose). If additional doses 
are need d, use Td.
• Children 7–10 years who receive Tdap 
inadvertently or as part of the catch-up series may 
receive the routine Tdap dose at 11–12 years.
• DTaP inadvertently given after the 7th birthday: 
 ɱ Child 7–10: DTaP may count as part of 
catch-up series. Routine Tdap dose at 11-12 
may be given.
 ɱ Adolescent 11–18: Count dose of DTaP as the 
adolescent Tdap booster. 
• For other catch-up guidance, see Figure 2.
14.  Human papillomavirus (HPV) vaccine (minimum
age: 9 years)
Routine and catch-up vaccination:
• Routine vaccination for all adolescents at 11–12 
y ars (can start at age 9) and through age 18 if 
not previously adequately vaccinated. Number of 
dose  d pendent on age at initial vacci at on: 
 ɱ Age 9–14 y ars at i itiat on: 2-dose series 
at 0 and 6–12 mon s. Minimum interval: 5 
months (repeat a ose given o soon at least 
12 weeks afte  the invalid do e and at le st 5 
months after the 1st dose).
 ɱ Age 15 years or older at initiation: 3-dose 
series at 0, 1–2 months, and 6 months. 
Mi imum intervals: 4 weeks between 1st  and 
2nd dose; 12 weeks between 2nd  and 3rd 
dose; 5 months betwee  1st and 3rd dose 
(repeat dose(s) given too soon at or after the 
mini um int rval since the ost r cent dose).
• Persons who have completed a valid series with 
any HPV vaccine do not need any additional doses. 
Special situations:
• History f sexual abuse or assault: Begin series at 
age 9 years.
• Immunocompromised* (including HIV) aged 
9–26 years: 3-dose series at 0, 1–2 months, and 6 
o ths.
• Pregnancy: Vaccinati n not recommended, 
but there is no evidence the vaccine is har ful. 
No intervention is n eded for women who 
inadvertentl  received a dose of HPV vaccine 
while pregnant. Delay remaining doses until after 
pregnancy. Pregnancy testing not needed before 
vaccination.
*See MMWR, December 16, 2016;65(49):1405–1408, 
at www.cdc.gov/mmwr/volumes/65/wr/pdfs/
mm6549a5.pdf.
